Anxiogenic effects of CGRP within the BNST may be mediated by CRF acting at BNST CRFR1 receptors

Behavioural Brain Research

Volumn 243, Issue 1, 2013, Pages 286-293

  Sink, K S ^a   Chung, A ^a   Ressler, K J ^a   Davis, M ^a   Walker, D L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Bed nucleus of the stria terminalis; Calcitonin gene related peptide; Corticotropin releasing factor; Fear; Startle

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CP 376395; GSK 876008; UNCLASSIFIED DRUG;

ACOUSTIC ANALYSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ANXIOGENIC ACTIVITY; ARTICLE; BED NUCLEUS OF THE STRIA TERMINALIS; BIOTINYLATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; STARTLE REFLEX; STRIA TERMINALIS;

AMINOPYRIDINES; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CATHETERIZATION; CELLS, CULTURED; CORTICOTROPIN-RELEASING HORMONE; GENETIC VECTORS; MALE; MAZE LEARNING; METHYLCELLULOSE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RNA, SMALL INTERFERING; SEPTAL NUCLEI; STARTLE REACTION;

EID: 84874358344     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.01.024     Document Type: Article

References (69)

1. Sullivan G.M., Apergis J., Bush D.E., Johnson L.R., Hou M., Ledoux J.E. Lesions in the bed nucleus of the stria terminalis disrupt corticosterone and freezing responses elicited by a contextual but not by a specific cue-conditioned fear stimulus. Neuroscience 2004, 128:7-14.
2. Waddell J., Morris R.W., Bouton M.E. Effects of bed nucleus of the stria terminalis lesions on conditioned anxiety: aversive conditioning with long-duration conditional stimuli and reinstatement of extinguished fear. Behavioral Neuroscience 2006, 120:324-336.
3. Walker D.L., Davis M. Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear. Journal of Neuroscience 1997, 17:9375-9383.
4. Sink K.S., Walker D.L., Yang Y., Davis M. Calcitonin gene-related peptide in the bed nucleus of the stria terminalis produces an anxiety-like pattern of behavior and increases neural activation in anxiety-related structures. Journal of Neuroscience 2011, 31:1802-1810.
5. Dobolyi A., Irwin S., Makara G., Usdin T.B., Palkovits M. Calcitonin gene-related peptide-containing pathways in the rat forebrain. Journal of Comparative Neurology 2005, 489:92-119.
6. Kainu T., Honkaniemi J., Gustafsson J.A., Rechardt L., Pelto-Huikko M. Co-localization of peptide-like immunoreactivities with glucocorticoid receptor- and Fos-like immunoreactivities in the rat parabrachial nucleus. Brain Research 1993, 615:245-251.
7. Kozicz T., Arimura A. Axon terminals containing CGRP-immunoreactivity form synapses with CRF- and Met-enkephalin-immunopositive neurons in the laterodorsal division of the bed nucleus of the stria terminalis in the rat. Brain Research 2001, 893:11-20.
8. Hauger R.L., Risbrough V., Oakley R.H., Olivares-Reyes J.A., Dautzenberg F.M. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Annals of the New York Academy of Sciences 2009, 1179:120-143.
9. Swerdlow N.R., Geyer M.A., Vale W.W., Koob G.F. Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (Berlin) 1986, 88:147-152.
10. Chalmers D.T., Lovenberg T.W., De Souza E.B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. Journal of Neuroscience 1995, 15:6340-6350.
11. Chen Y., Brunson K.L., Muller M.B., Cariaga W., Baram T.Z. Immunocytochemical distribution of corticotropin-releasing hormone receptor type-1 (CRF(1))-like immunoreactivity in the mouse brain: light microscopy analysis using an antibody directed against the C-terminus. Journal of Comparative Neurology 2000, 420:305-323.
12. Rominger D.H., Rominger C.M., Fitzgerald L.W., Grzanna R., Largent B.L., Zaczek R. Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies. Journal of Pharmacology and Experimental Therapeutics 1998, 286:459-468.
13. Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., Arias C., et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. Journal of Comparative Neurology 2000, 428:191-212.
14. Lee Y., Davis M. Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. Journal of Neuroscience 1997, 17:6434-6446.
15. Sahuque L.L., Kullberg E.F., McGeehan A.J., Kinder J.R., Hicks M.P., Blanton M.G., et al. Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes. Psychopharmacology (Berlin) 2006, 186:122-132.
16. Lee Y., Fitz S., Johnson P.L., Shekhar A. Repeated stimulation of CRF receptors in the BNST of rats selectively induces social but not panic-like anxiety. Neuropsychopharmacology 2008, 33:2586-2594.
17. Liang K.C., Chen H.C., Chen D.Y. Posttraining infusion of norepinephrine and corticotropin releasing factor into the bed nucleus of the stria terminalis enhanced retention in an inhibitory avoidance task. Chinese Journal of Physiology 2001, 44:33-43.
18. Ciccocioppo R., Fedeli A., Economidou D., Policani F., Weiss F., Massi M. The bed nucleus is a neuroanatomical substrate for the anorectic effect of corticotropin-releasing factor and for its reversal by nociceptin/orphanin FQ. Journal of Neuroscience 2003, 23:9445-9451.
19. Nijsen M.J., Croiset G., Diamant M., De Wied D., Wiegant V.M. CRH signalling in the bed nucleus of the stria terminalis is involved in stress-induced cardiac vagal activation in conscious rats. Neuropsychopharmacology 2001, 24:1-10.
20. Walker D., Yang Y., Ratti E., Corsi M., Trist D., Davis M. Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses. Neuropsychopharmacology 2009, 34:1533-1542.
21. Kovacs A., Biro E., Szeleczky I., Telegdy G. Role of endogenous CRF in the mediation of neuroendocrine and behavioral responses to calcitonin gene-related peptide in rats. Neuroendocrinology 1995, 62:418-424.
22. Bowe J.E., Li X.F., Kinsey-Jones J.S., Brain S.D., Lightman S.L., O'Byrne K.T. The role of corticotrophin-releasing hormone receptors in the calcitonin gene-related peptide-induced suppression of pulsatile luteinising hormone secretion in the female rat. Stress 2008, 11:312-319.
23. Kocorowski L.H., Helmstetter F.J. Calcitonin gene-related peptide released within the amygdala is involved in Pavlovian auditory fear conditioning. Neurobiology of Learning and Memory 2001, 75:149-163.
24. Di Fabio R., St-Denis Y., Sabbatini F.M., Andreotti D., Arban R., Bernasconi G., et al. Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists. Journal of Medicinal Chemistry 2008, 51:7370-7379.
25. Rattiner L.M., Davis M., French C.T., Ressler K.J. Brain-derived neurotrophic factor and tyrosine kinase receptor B involvement in amygdala-dependent fear conditioning. Journal of Neuroscience 2004, 24:4796-4806.
26. Ressler K.J., Paschall G., Zhou X.L., Davis M. Regulation of synaptic plasticity genes during consolidation of fear conditioning. Journal of Neuroscience 2002, 22:7892-7902.
27. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego. 3rd ed.
28. Walker D.L., Davis M. Quantifying fear potentiated startle using absolute versus proportional increase scoring methods: implications for the neurocircuitry of fear and anxiety. Psychopharmacology (Berlin) 2002, 164:318-328.
29. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacology Biochemistry and Behavior 1996, 54:21-30.
30. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacology Biochemistry and Behavior 1986, 24:525-529.
31. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacology Biochemistry and Behavior 1994, 49:171-176.
32. Bale T.L., Vale W.W.C.R.F CRF receptors: role in stress responsivity and other behaviors. Annual Review of Pharmacology and Toxicology 2004, 44:525-557.
33. Risbrough V.B., Stein M.B. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Hormones and Behavior 2006, 50:550-561.
34. Britton D.R., Koob G.F., Rivier J., Vale W. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sciences 1982, 31:363-367.
35. Dunn A.J., File S.E. Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Hormones and Behavior 1987, 21:193-202.
36. Veldhuis H.D., De Wied D. Differential behavioral actions of corticotropin-releasing factor (CRF). Pharmacology Biochemistry and Behavior 1984, 21:707-713.
37. Berridge C.W., Dunn A.J. CRF and restraint-stress decrease exploratory behavior in hypophysectomized mice. Pharmacology Biochemistry and Behavior 1989, 34:517-519.
38. Spadaro F., Berridge C.W., Baldwin H.A., Dunn A.J. Corticotropin-releasing factor acts via a third ventricle site to reduce exploratory behavior in rats. Pharmacology Biochemistry and Behavior 1990, 36:305-309.
39. Krahn D.D., Gosnell B.A., Levine A.S., Morley J.E. Behavioral effects of corticotropin-releasing factor: localization and characterization of central effects. Brain Research 1988, 443:63-69.
40. Takahashi L.K., Kalin N.H., Vanden Burgt J.A., Sherman J.E. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behavioral Neuroscience 1989, 103:648-654.
41. Yang X.M., Dunn A.J. Central beta 1-adrenergic receptors are involved in CRF-induced defensive withdrawal. Pharmacology Biochemistry and Behavior 1990, 36:847-851.
42. Liang K.C., Melia K.R., Miserendino M.J., Falls W.A., Campeau S., Davis M. Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. Journal of Neuroscience 1992, 12:2303-2312.
43. Buwalda B., de Boer S.F., Van Kalkeren A.A., Koolhaas J.M. Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin-releasing factor in the rat. Psychoneuroendocrinology 1997, 22:297-309.
44. Song C., Earley B., Leonard B.E. Behavioral, neurochemical, and immunological responses to CRF administration. Is CRF a mediator of stress?. Annals of the New York Academy of Sciences 1995, 771:55-72.
45. Somerville L.H., Whalen P.J., Kelley W.M. Human bed nucleus of the stria terminalis indexes hypervigilant threat monitoring. Biological Psychiatry 2010, 68:416-424.
46. Straube T., Mentzel H.J., Miltner W.H. Waiting for spiders: brain activation during anticipatory anxiety in spider phobics. NeuroImage 2007, 37:1427-1436.
47. Fox A.S., Shelton S.E., Oakes T.R., Converse A.K., Davidson R.J., Kalin N.H. Orbitofrontal cortex lesions alter anxiety-related activity in the primate bed nucleus of stria terminalis. Journal of Neuroscience 2010, 30:7023-7027.
48. Sink KS, Walker DL, Freeman SM, Flandreau EI, Ressler KJ, Davis M. Effects of continuously enhanced corticotropin releasing factor expression within the bed nucleus of the stria terminalis on conditioned and unconditioned anxiety. Molecular Psychiatry; in press.
49. Ju G., Han Z.S. Coexistence of corticotropin releasing factor and neurotensin within oval nucleus neurons in the bed nuclei of the stria terminalis in the rat. Neuroscience Letters 1989, 99:246-250.
50. Merchenthaler I., Vigh S., Petrusz P., Schally A.V. Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. The American Journal of Anatomy 1982, 165:385-396.
51. Grammatopoulos D.K., Chrousos G.P. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends in Endocrinology and Metabolism: TEM 2002, 13:436-444.
52. Skorzewska A., Lehner M., Hamed A., Wislowska-Stanek A., Turzynska D., Sobolewska A., et al. The effect of CRF2 receptor antagonists on rat conditioned fear responses and c-Fos and CRF expression in the brain limbic structures. Behavioural Brain Research 2011, 221:155-165.
53. Takahashi C., Ohata H., Shibasaki T. Corticotropin-releasing factor (CRF) receptor subtypes in mediating neuronal activation of brain areas involved in responses to intracerebroventricular CRF and stress in rats. Peptides 2011, 32:2384-2393.
54. Zhao Y., Valdez G.R., Fekete E.M., Rivier J.E., Vale W.W., Rice K.C., et al. Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats. Journal of Pharmacology and Experimental Therapeutics 2007, 323:846-854.
55. Valdez G.R., Sabino V., Koob G.F. Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. Alcoholism, Clinical and Experimental Research 2004, 28:865-872.
56. Hannibal J. Pituitary adenylate cyclase-activating peptide in the rat central nervous system: an immunohistochemical and in situ hybridization study. Journal of Comparative Neurology 2002, 453:389-417.
57. Dabrowska J., Hazra R., Ahern T.H., Guo J.D., McDonald A.J., Mascagni F., et al. Neuroanatomical evidence for reciprocal regulation of the corticotrophin-releasing factor and oxytocin systems in the hypothalamus and the bed nucleus of the stria terminalis of the rat: implications for balancing stress and affect. Psychoneuroendocrinology 2011, 36:1312-1326.
58. Hammack S.E., Roman C.W., Lezak K.R., Kocho-Shellenberg M., Grimmig B., Falls W.A., et al. Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress. Journal of Molecular Neuroscience: MN 2010, 42:327-340.
59. Gauriau C., Bernard J.F. Pain pathways and parabrachial circuits in the rat. Experimental Physiology 2002, 87:251-258.
60. Han J.S., Adwanikar H., Li Z., Ji G., Neugebauer V. Facilitation of synaptic transmission and pain responses by CGRP in the amygdala of normal rats. Molecular Pain 2010, 6:10.
61. Paxinos G. The Rat Nervous System 2004, Academic Press, San Diego, CA (USA). 3rd ed.
62. Rodaros D., Caruana D.A., Amir S., Stewart J. Corticotropin-releasing factor projections from limbic forebrain and paraventricular nucleus of the hypothalamus to the region of the ventral tegmental area. Neuroscience 2007, 150:8-13.
63. Moga M.M., Saper C.B., Gray T.S. Bed nucleus of the stria terminalis: cytoarchitecture, immunohistochemistry, and projection to the parabrachial nucleus in the rat. Journal of Comparative Neurology 1989, 283:315-332.
64. Panguluri S., Saggu S., Lundy R. Comparison of somatostatin and corticotrophin-releasing hormone immunoreactivity in forebrain neurons projecting to taste-responsive and non-responsive regions of the parabrachial nucleus in rat. Brain Research 2009, 1298:57-69.
65. Gray T.S., Magnuson D.J. Neuropeptide neuronal efferents from the bed nucleus of the stria terminalis and central amygdaloid nucleus to the dorsal vagal complex in the rat. Journal of Comparative Neurology 1987, 262:365-374.
66. Gray T.S., Magnuson D.J. Peptide immunoreactive neurons in the amygdala and the bed nucleus of the stria terminalis project to the midbrain central gray in the rat. Peptides 1992, 13:451-460.
67. Champagne D., Beaulieu J., Drolet G. CRFergic innervation of the paraventricular nucleus of the rat hypothalamus: a tract-tracing study. Journal of Neuroendocrinology 1998, 10:119-131.
68. Alvarez R.P., Chen G., Bodurka J., Kaplan R., Grillon C. Phasic and sustained fear in humans elicits distinct patterns of brain activity. NeuroImage 2011, 55:389-400.
69. Greenberg B.D., Gabriels L.A., Malone D.A., Rezai A.R., Friehs G.M., Okun M.S., et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Molecular Psychiatry 2010, 15:64-79.